January 6th, 2025 “EURETINA-Brief”© Issue No. 307
Dear EURETINA Members, A very warm welcome to the January 6th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
January 6th, 2025
Latest News
January 6th, 2025 “EURETINA-Brief”© Issue No. 307
Dear EURETINA Members, A very warm welcome to the January 6th, 2025 edition of EURETINA’s…
The D126G mutation in RS1 gene, causing X-linked juvenile retinoschisis (XLRS), shows the highest prevalence of the disorder in a Thailand study.
Researchers at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand, have…
A nationwide study on the incidence of rare retinal diseases in South Korea reports 1.1M clinical records.
Researchers at the Department of Ophthalmology, Seoul National University College of Medicine, South Korea, have…
Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that aflibercept (injection 8 mg) met the primary…